Search

Your search keyword '"Martínez-Rojas, Miguel Ángel"' showing total 9 results
Start Over Author "Martínez-Rojas, Miguel Ángel"
9 results on '"Martínez-Rojas, Miguel Ángel"'

4. [Untitled]

Author

Pedro León Pérez Curcho Diana del Carmen Valencia Perea Javier Rivera Márquez Alfredo Alejandro Guzmán Becerra José Muñoz Flores María José Ibarrola RIvas Víctor Raúl Apolaya Sarmiento Caszely Orlando Rivera Huarancca Carlos Humberto Alfaro Rodríguez Julio Torres Guzmán Miguel Antony Curo Quispe Diego Omar Guevara Torrecillas Wilington Ferney Rojas González Yeymy Lizeth Estrada Orozco Shyrley Rocio Vargas Paredes Diana Katerine Rojas Vargas Mariana Lobato Báez Luis Alberto Morales Rosales Dulce María Martínez Angeles Elmar Montiel Jiménez María del Pilar García Barrera Melany Amandra Bustos Carpio Henri Emmanuel Lopez Gomez Juan Manuel Sanchez Soto Luis Antonio Visurraga Camargo Victor Alfonso Landeo Julcarima Cristian Fernan Muñoz Muñoz Felipe Lozano Rodríguez Israel Barrutia Barreto Gil Gumercindo Quillama Virto Silvia Cristina Campos Quispe Rumania Alexandra Torres Navarrete Gabriela Elizabeth Izurieta Romero Marco Oviedo Rodriguez Patricia del Rocío Ramírez Contreras Segundo Bolier Torres Navarrete Mariana Lobato Báez Luis Alberto Morales Rosales Ignacio Algredo Badillo María del Rosario Hernández Gracia José Luis Trejo Mirón Julisa Yrelsa Chavéz Guillén Gilber Chura Quispe Lady Antuanette Leyva Ato Julio Cesar Suarez Luna Miccy Lissethe Bonilla Banda María Cecilia Tamayo Buitrago Melissa Moncada Vega Martha Lucia Gazon Osorio Israel Barrutia Barreto Olga Isabel Carbajal Guerrero Felix Alberto Caycho Valencia Reyna Olano Del Castillo José Carlos Rodríguez Chacón Patricia Paulina Huarancca Contreras Henry Genaro Guevara Garibay Eduardo Antonio Navarrete Senda Paulina Eliades Yarasca Carlos NELLY KARINA ESPARZA CRUZ María Isabel Gonzales Valero Ana del Rocio Fernández Torres Narcisa María Crespo Torres Elisa Candida Garavito Checalla Vidnay Noel Valero Ancco Marcial Guevara Mamani William Elbis Hilasaca Yujra Andrés Julián Guzmán Sierra Laura Marcela Jiménez Vega Leidy Morales Hernández Zoila Rosa Lira Camargo Edward Iván Terrones Gálvez Jorge Lira Camargo Stefany Viviana Morales Hernández Karel Llopiz Guerra Dante De la Cruz Cámaco Johnny de la Cruz Cámaco Luis Miguel Rojas Zuñiga Carlos Alberto Valderrama Zapata Manuel Antonio Cardoza Sernaqué Omar Bellido Valdiviezo Henry Alberto Chero Valdivieso Juan Pablo Moreno Muro Luis Alexander Pulido Joo Damiana Flores Mamani Ronny Eliberto Pongo Yucra Gustavo Alberto Reyna Arauco Marisol Condori Apaza Julio Cesar Suarez Luna Miccy Lissethe Bonilla Banda Angel Johel Centurión Larrea Israel Barrutia Barreto Renzo Seminario Córdova José Lisbinio Cruz Guimaraes Vanessa Martínez Rojas Miguel Ángel Castillo Corzo Claudia Liliana Felles Isidro Pascual Víctor Sarmiento Maza Nadia Beatriz Rea Dionicio Ana Melva Contreras Contreras Joel Elvys Alanya Beltran Frans Ramiro Cárdenas Palomino Luis Fernando Velarde Vela Freddy Antonio Ochoa Tataje Sara Edith Castillo Olsson Martha Irene Bello Ramírez Mariana Lobato Báez Jonathan Belen Rodríguez Juan Carlos Rosales Espinoza José Alberto Sánchez López Dulce María de Jesús Delgado Cih Sagrario María Quijano Gutiérrez Geidy de los Ángeles Gómez Xul Fernando Romero Torres Augusto Renato Pérez Mayo Marisa del Rosario Estrada Carrillo Arely Ruelas Angulo Nohemi Roque Nieto Mariana Lobato Báez Luis Alberto Morales Rosales Angelina Leal Alvarado Guillermo Córdova Morales Martha Irene Bello Ramírez Jorge Luis Apaza Cruz Mary Luz Limachi Flores Marco Antonio Quispe Barra IVAN DELGADO HUAYTA JAMES ROLANDO ARREDONDO MAMANI Angel Johel Centurión Larrea Milagros Macedo Cieza Manuel Arancibia Figueroa Víctor German Aguilar De La Cruz Marisol Fustamante Vasquez Harold Antony Davila Villalobos Cesar Augusto Silva Giraldo Yohanna Milena Rueda Mahecha Angélica María Moreno Cesar Augusto Silva Giraldo, David Andres Suarez Suarez, Roxana Pinilla Duarte Coordinadores editoriales: Centro de Investigación Científica, Empresarial y Tecnológica de Colombia – CEINCET, Red de Investigación en Educación, Empresa y Sociedad – REDIEES, Escuela Internacional de Negocios y Desarrollo Empresarial de Colombia – EIDEC

Published
2022
Full Text
View/download PDF

6. Urinary serpin-A3 is an early predictor of clinical response to therapy in patients with proliferative lupus nephritis.

Author

Martínez-Rojas, Miguel Ángel, Sánchez-Navarro, Andrea, Mejia-Vilet, Juan Manuel, Pérez-Villalva, Rosalba, Uribe, Norma, and Bobadilla, Norma A.

Subjects
*LUPUS nephritis, *TREATMENT effectiveness, *WESTERN immunoblotting, *MEXICANS
Abstract

We have previously reported that urinary excretion of serpin-A3 (uSerpA3) is significantly elevated in patients with active lupus nephritis (LN). Here, we evaluated the course of uSerpA3 during the first year of treatment and its association with response to therapy in patients with proliferative LN. The observational longitudinal study included 60 Mexican adults with proliferative LN followed during the first year after LN flare. uSerpA3 was detected by Western blot analysis at flare and after 3, 6, and 12 mo. The response to therapy was determined 1 yr after the LN flare. We evaluated the correlation between uSerpA3 and histological parameters at LN flare. The temporal association between uSerpA3 and response to therapy was analyzed with linear mixed models. uSerpA3 prognostic performance for response was evaluated with receiver-operating characteristic curves. Among the 60 patients studied, 21 patients (35%) were class III and 39 patients (65%) were class IV. uSerpA3 was higher in class IV than in class III LN (6.98 vs. 2.89 dots per in./mg creatinine, P = 0.01). Furthermore, uSerpA3 correlated with the histological activity index (r = 0.29, P = 0.02). There was a significant association between the temporal course of uSerpA3 and response to therapy. Responders showed a significant drop in uSerpA3 at 6 mo compared with LN flare (P < 0.001), whereas nonresponders persisted with elevated uSerpA3. Moreover, uSerpA3 was significantly lower at flare in responders compared with nonresponders (2.69 vs. 6.98 dots per in./mg creatinine, P < 0.05). Furthermore, uSerpA3 was able to identify nonresponders since 3 mo after LN flare (area under the curve: 0.77). In conclusion, uSerpA3 is an early indicator of kidney inflammation and predictor of the clinical response to therapy in patients with proliferative LN. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

8. Supplementary table 1

Author

Sanchez-Navarro, Andrea, Martínez-Rojas, Miguel Ángel, Caldiño-Bohn, Rebecca I., Pérez-Villalva, Rosalba, Zambrano, Elena, Castro-Rodríguez, Diana C., and Bobadilla, Norma A.

Abstract

Supplementary Table 1. Physiological parameters in mice fed a MHFD compared to the C group at the en of the study. These metabolic results were partially published (9). The group fed a standard diet (C) and the MHFD group. n=10/11 per group, respectively. Data are expressed as means ± SEM, data are statistically different, with p < 0.05.

Published
2021
Full Text
View/download PDF

9. Transient inhibition of sodium-glucose cotransporter 2 after ischemia/reperfusion injury ameliorates chronic kidney disease.

Author

Martínez-Rojas MÁ, Balcázar H, González-Soria I, González-Rivera JM, Rodríguez-Vergara ME, Velazquez-Villegas LA, León-Contreras JC, Pérez-Villalva R, Correa F, Rosetti F, and Bobadilla NA

Subjects
Animals, Humans, Male, Rats, Glucose, Rats, Wistar, Sodium metabolism, Sodium-Glucose Transporter 2 drug effects, Sodium-Glucose Transporter 2 Inhibitors pharmacology, Sodium-Glucose Transporter 2 Inhibitors therapeutic use, Benzhydryl Compounds pharmacology, Benzhydryl Compounds therapeutic use, Acute Kidney Injury drug therapy, Acute Kidney Injury prevention & control, Acute Kidney Injury metabolism, Renal Insufficiency, Chronic drug therapy, Reperfusion Injury complications, Reperfusion Injury metabolism
Abstract

Sodium-glucose cotransporter 2 (SGLT2) inhibitor, dapagliflozin (Dapa), exhibited nephroprotective effects in patients with chronic kidney disease (CKD). We assessed the efficacy of short-term Dapa administration following acute kidney injury (AKI) in preventing CKD. Male Wistar rats were randomly assigned to Sham surgery, bilateral ischemia for 30 minutes (abbreviated as IR), and IR + Dapa groups. Daily treatment with Dapa was initiated just 24 hours after IR and maintained for only 10 days. Initially, rats were euthanized at this point to study early renal repair. After severe AKI, Dapa promptly restored creatinine clearance (CrCl) and significantly reduced renal vascular resistance compared with the IR group. Furthermore, Dapa effectively reversed the mitochondrial abnormalities, including increased fission, altered mitophagy, metabolic dysfunction, and proapoptotic signaling. To study this earlier, another set of rats was studied just 5 days after AKI. Despite persistent renal dysfunction, our data reveal a degree of mitochondrial protection. Remarkably, a 10-day treatment with Dapa demonstrated effectiveness in preventing CKD transition in an independent cohort monitored for 5 months after AKI. This was evidenced by improvements in proteinuria, CrCl, glomerulosclerosis, and fibrosis. Our findings underscore the potential of Dapa in preventing maladaptive repair following AKI, emphasizing the crucial role of early intervention in mitigating AKI long-term consequences.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results